Intraperative, intravascular and endoscopic tumor and lesion detection and therapy with monovalent antibody fragments

• US 5,716,595 A
• Filed: 08/22/1994
• Issued: 02/10/1998
• Est. Priority Date: 05/06/1992
• Status: Expired due to Term

• Current Assignee: Immunomedics, Inc.
• Original Assignee: Immunomedics, Inc.
• Inventors: Goldenberg, David M.
• Primary Examiner(s): Feisee, Lila
• Assistant Examiner(s): Gambel, Phillip
• Application Number:
  US08/293,313
• Time in Patent Office: 1,268 Days
• Field of Search: 464/1.11, 464/1.49, 464/178.1, 464/181.1
• US Class Current: 424/1.49
• CPC Class Codes: A61K 2121/00 Preparations for use in therapy
• CPC Class Codes: A61K 2123/00 Preparations for testing in vivo
• CPC Class Codes: A61K 47/6898 using avidin- or biotin-conjugated antibodies
• CPC Class Codes: A61K 49/0036 Porphyrins used in photodynamic therapy A61K41/0071 or A61K41/0076; used as targeting group or modifying agent for targeting a therapeutic compound A61K47/546
• CPC Class Codes: A61K 49/0058 Antibodies
• CPC Class Codes: A61K 51/1048 the tumor cell determinant being a carcino embryonic antigen
• CPC Class Codes: A61K 51/1072 the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
• CPC Class Codes: A61K 51/1093 conjugates with carriers being antibodies
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Methods are provided for close-range intraoperative, endoscopic and intravascular detection and treatment of lesions, including tumors and non-malignant lesions. The methods use agents labeled with isotopic and non-isotopic agents. Also provided are methods for detection and treatment of lesions with photodynamic agents and methods of treating lesions with a protein conjugated to an agent capable of being activated to emit Anger electron or other ionizing radiation. Compositions and kits useful in the above methods are also provided.

Claims

1. A method for close-range tumor detection and, optionally, treatment, during an operative, intravascular or endoscopic procedure, wherein the method comprises the steps of:

injecting a patient subject to such a procedure parenterally with an effective amount of a labeled monovalent antibody fragment or subfragment which specifically binds antigen produced by or associated with a tumor;

conducting the procedure within 48 hours of the injection;

scanning the accessed interior of the patient at close range with a detection means for detecting the presence of the labeled antibody fragment or subfragment;

locating the sites of accretion of the labeled antibody fragment or subfragment by detecting elevated levels of the labeled antibody fragment or subfragment at such sites with the detection means, without the use of a clearing agent, contrast agent or subtraction agent, and optionally, treating the detected sites of accretion of said labeled antibody fragment or subfragment.

2. The method of claim 1, wherein the procedure is conducted within 24 hours of the injection.

3. The method of claim 1, wherein the procedure is conducted within 12 hours of the injection.

4. The method of claim 1, wherein the procedure is conducted within 6 hours of the injection.

5. The method of claim 1, wherein the fragment or subfragment is a monoclonal antibody fragment or subfragment.

6. The fragment of claim 5, which is an Fv, single-chain antibody, Fab or Fab'"'"' fragment.

7. The method of claim 1, wherein the label for the fragment or subfragment is a radioisotope.

8. The method of claim 7, wherein the radioisotope emits at an energy of 20-1,000 KeV.

9. The method of claim 7, wherein the radioisotope is technetium-99m.

10. The method of claim 7, wherein the radioisotope is iodine-125, iodine-131 or iodine-123.

11. The method of claim 7, wherein the radioisotope is indium-111.

12. The method of claim 7, wherein the radioisotope is gallium-67.

13. The method of claim 1, wherein the label of said labeled antibody fragment or subfragment is a non-isotopic agent.

14. The method of claim 13, wherein the non-isotopic agent is a photoactive agent.

15. The method of claim 14, wherein the photoactive agent is a fluorescent agent.

16. The method of claim 1, wherein the method further comprises treating detected sites during the procedure.

17. The method of claim 1, wherein the procedure is an operative procedure.

18. The method of claim 1, wherein the procedure is an intravascular procedure.

19. The method of claim 1, wherein the procedure is an endoscopic procedure.

20. The method of claim 1, wherein said procedure is a laparoscopic procedure.

21. The method of claim 1, further comprising treating the tumor during the procedure by brachytherapy, external beam radiation, laser therapy or surgical removal.

22. A method of detection of lesions during an endoscopic, intravascular catheter or surgical procedure, wherein the method comprises the steps of:

injecting a patient to undergo such a procedure with an antibody fragment or subfragment labeled with a fluorescent agent or dye, wherein the labeled antibody fragment or subfragment accretes at the lesion;

permitting the labeled antibody fragment or subfragment to accrete;

conducting the procedure within 48 hours of the injection; and

detecting the label with a light source supplied via an endoscope or intravascular catheter or during the surgical procedure, without the use of a clearing agent, contrast agent or subtraction agent.

23. The method of claim 22, further comprising the step of removing lesions at sites of elevated label accretion with a laser or surgically.

24. The method of claim 22, further comprising the step of treating lesions at sites of elevated label accretion with ionizing radiation.

25. The method of claim 24, wherein the procedure is selected from the group consisting of endoscopic and intravascular catheter procedures, and further comprising the step of administering brachytherapy via the endoscope or catheter to lesions at sites of elevated label accretion.

26. The method of claim 22, wherein the antibody fragment is selected from the group consisting of an Fv, single-chain antibody, Fab, Fab'"'"', F(ab)₂ and F(ab'"'"')₂ fragment.

27. The method of claim 22, wherein the lesion is selected from the group consisting of a cancer, infectious or inflammatory lesion, clot, hyperplasia and atherosclerotic plaque.

28. The method of claim 22, wherein said procedure is conducted within 24 hours of the injection of said labeled antibody fragment or subfragment.

29. The method of claim 22, wherein said procedure is a laparoscopic procedure.

30. A method of detection and treatment of lesions during an endoscopic or intravascular catheter procedure, wherein the method comprises the steps of:

(a) injecting a patient to undergo such a procedure with an antibody fragment or subfragment labeled with an agent capable of detection, which labeled antibody fragment or subfragment preferentially accretes at the lesion;

(b) permitting the labeled antibody fragment or subfragment to accrete at the lesion;

(c) conducting the procedure within 48 hours of the injection of the labeled antibody fragment or subfragment;

(d) detecting the agent with a detection means supplied via the endoscope or intravascular catheter, wherein the agent is detected without the use of a clearing agent, contrast agent or subtraction agent; and

(e) treating the lesion by brachytherapy administered through the endoscope or intravascular catheter.

31. The method of claim 30, wherein the antibody fragment is an Fv, single-chain antibody, Fab, Fab'"'"', F(ab)₂ or F(ab'"'"')₂.

32. The method of claim 30, wherein the lesion is a cancer, infectious or inflammatory lesion, clot, hyperplasia or atherosclerotic plague.

33. The method of claim 30, wherein said procedure is conducted within 24 hours of the injection of said labeled antibody fragment or subfragment.

34. The method of claim 30, wherein said procedure is a laparoscopic procedure.

35. A method of treatment of lesions during a laparoscopic or intravascular catheter procedure, wherein the method comprised the steps of:

injecting a patient to undergo such a procedure with an antibody fragment or subfragment labeled with a photoactive agent, wherein the antibody fragment or subfragment preferentially accretes at targeted lesions;

permitting the labeled antibody fragment or subfragment to accrete;

conducting the procedure within 48 hours of the injection of the labeled antibody or subfragment; and

activating the photoactive agent with a light source supplied via the laparascope or intravascular catheter, thereby treating said lesions.

36. The method of claim 35, wherein the lesion is a cancer, infectious or inflammatory lesion, clot, hyperplasia or atherosclerotic plaque.

37. The method of claim 35, wherein said procedure is conducted within 24 hours of the injection of said labeled antibody fragment or subfragment.

38. A method of treatment of lesions, wherein the method comprises the steps of:

(a) injecting a patient with composition comprising a protein conjugated to an agent capable of being activated to emit Auger electrons or other ionizing radiation, and, optionally, to an agent capable of detection, wherein the protein conjugate accretes preferentially at the targeted lesion; and

(b) activating said agent capable of being activated, thereby treating said lesions, and, optionally, detecting the optional agent capable of detection.

39. The method of claim 38, wherein the activation and optional detection is during an endoscopic, intravascular, catheter or surgical procedure.

40. The method of claim 39, wherein said procedure is a laparoscopic procedure.

41. The method of claim 38, wherein the activatable agent is a stable element capable of being activated to emit ionizing radiation.

42. The method of claim 38, wherein the activatable agent is a stable element capable of being activated to emit Auger electrons.

43. The method of claim 42, wherein the activatable agent is a halogenated compound.

44. The method of claim 43, wherein the agent is a halogenated pyrimidine.

45. The method of claim 41, wherein the stable element is iodine or indium.

46. The method of claim 38, wherein the protein is a peptide, polypeptide, growth factor, hormone, lymphokine, cytokine, receptor protein, immune modulator, enzyme, antibody or antibody fragment.

47. The method of claim 46, wherein the antibody fragment is an Fv, single-chain antibody, Fab, Fab'"'"', F(ab)₂ or F(ab'"'"')₂.

48. The method of claim 46, wherein the antibody or antibody fragment is a monoclonal antibody.

49. The method of claim 38, wherein the activating energy is monochromatic X-rays.

50. The method of claim 49, wherein the monochromatic X-rays emit at an energy of 20-70 KeV.

51. The method of claim 50, wherein the monochromatic X-rays emit at an energy of 30-40 KeV.

52. The method of claim 38, wherein the lesion is a cancer, infectious or inflammatory lesion, clot, hyperplasia or atherosclerotic plague.